persevERA: First Line Treatment with Giredestrant or Letrozole in Combination With Palbociclib in ER-Positive HER2-Negative Advanced/Metastatic Breast Cancer
Condition: Breast Cancer
Sponsor: Hoffmann-La Roche
Full Title
Protocol BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Eligibility
Eligible patients will have locally advanced (recurrent or progressive) or metastatic ER-positive and HER2-negative breast cancer with recurrence from early stage breast cancer after at least 24 months of treatment with an aromatase inhibitor and at least a 12 month disease free interval after the completion of aromatase inhibitor treatment.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
